

# Evaluation of Hereditary Risk in a Screening Mammography Population

Julie L. Jones, Kevin S. Hughes, Daniel B. Kopans, Richard H. Moore, Marissa Howard-McNatt, Sherwood S. Hughes, Nancy Y. Lee, Constance A. Roche, Nancy Siegel, Michele A. Gadd, Barbara L. Smith, James S. Michaelson

## Abstract

**PURPOSE:** *BRCA1* and *BRCA2* mutations significantly increase a woman's lifetime risk of breast and ovarian cancer. Because several management options have shown promise in decreasing morbidity and mortality for these women, identifying potential mutation carriers is increasingly important. We developed a large-scale method to collect family histories in a population of unaffected women presenting for mammography. We then applied current risk-assessment models to determine the prevalence of women at risk for hereditary breast and ovarian cancer. **MATERIALS AND METHODS:** We performed a retrospective review of family histories using data collected on all unaffected women presenting for mammography over a 14-week period. The Claus, Myriad II, and Hartmann models for hereditary risk assessment were applied to the survey results. **RESULTS:** Five thousand seven hundred thirty-six women completed the questionnaire, of whom 695 with a personal history of breast or ovarian cancer were excluded. Family histories of the remaining 5,041 women were evaluated. Totals of 5.9%, 5.2%, and 3.3% of patients, respectively, met criteria for increased risk according to the Hartmann, Myriad II, and Claus models, corresponding to 3.5, 3.1, and 1.9 patients per day. Although 9.2% of patients met criteria for  $\geq 1$  model, only 1.4% met criteria for all 3. **CONCLUSIONS:** Application of available models to a screening population classifies a larger than expected number of women at high risk for a *BRCA1* or *BRCA2* mutation. New approaches to risk assessment and counseling are needed to apply our knowledge of hereditary risk to a broad population in a practical manner.

*Clinical Breast Cancer*, Vol. 6, No. 1, ???-???, 2005

**Key words:** *BRCA1*, *BRCA2*, Hereditary breast cancer, Hereditary ovarian cancer, Risk assessment

## Introduction

The presence of *BRCA1* and *BRCA2* mutations are estimated to increase a woman's lifetime breast cancer risk to 50%-80% and the lifetime ovarian cancer risk to 10%-40%.<sup>1</sup> Data are accumulating in support of several management options for these women, including intensified screening, chemoprevention, bilateral prophylactic mastectomy, and prophylactic oophorectomy. Identifying potential mutation carriers is therefore important to potentially decrease the morbidity and mortality of cancer in these individuals.

There is evidence that bilateral prophylactic mastectomy significantly decreases the incidence of breast cancer in *BRCA1* and *BRCA2* mutation carriers. Meijers-Heijboer et al prospectively followed 139 mutation carriers.<sup>2</sup> Eight of 63 patients under surveillance developed breast cancer, whereas no cases of breast cancer occurred among 76 women who underwent prophylactic surgery ( $P = 0.003$ ; hazard ratio, 0). Two recent studies have shown significant benefit of prophylactic salpingo-oophorectomy in reducing ovarian cancer incidence in *BRCA1* and *BRCA2* mutation carriers. Kauff et al reported 170 women with *BRCA* mutations followed prospectively for a mean of 24.2 months.<sup>3</sup> Ninety-eight women underwent prophylactic surgery, and the hazard ratio for *BRCA*-associated gynecologic cancers was 0.15. Rebbeck et al reported on 551 mutation carriers identified retrospectively and prospectively.<sup>4,5</sup> Two hundred

---

Massachusetts General Hospital, Boston, Massachusetts

Submitted: ???; Revised: ???; Accepted: ???

Address for correspondence: Kevin S. Hughes, MD, Massachusetts General Hospital, 100 Blossom St, Cox 626, Boston, MA 02114

Fax: 617-724-3895; e-mail: kshughes@partners.org

---

Electronic forwarding or copying is a violation of US and International Copyright Laws. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cancer Information Group, ISSN #1526-8209, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

**Table 1** Patients Meeting Criteria for Each Model\*

Model	Patients Meeting Criteria	Patients Studied
Myriad II	263	5.2%
Hartmann	295	5.9%
Claus	168	3.3%

\*Patients may be counted more than once.

fifty-nine women followed for a mean of 6.2 years after prophylactic surgery had a hazard ratio of 0.04 for the development of coelomic epithelial cancer. Prophylactic oophorectomy also appears to reduce the incidence of breast cancer in *BRCA* mutation carriers, particularly before menopause. Data on the effect of tamoxifen use in *BRCA* mutation carriers are still preliminary. In a retrospective analysis from the Hereditary Breast Cancer Clinical Study Group, tamoxifen reduced the risk of contralateral breast cancer in *BRCA1* and *BRCA2* mutation carriers.<sup>6</sup> In a subgroup analysis from the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial, however, tamoxifen appeared to decrease breast cancer incidence among *BRCA2* mutation carriers but not among *BRCA1* mutation carriers.<sup>7</sup> Therefore, tamoxifen use in this population appears useful for risk reduction in *BRCA2* mutation carriers but its effectiveness in *BRCA1* mutation carriers requires further clarification.

For these strategies to have a significant impact, women at risk of having a *BRCA1* or *BRCA2* mutation must be identified in large numbers before they develop cancer. However, the best methods for identifying these individuals at high risk and the criteria to quantify their risk have not yet been agreed upon. Several models have been developed to aid in breast cancer risk assessment. The earliest of these, the Gail and Claus models, were based on correlation between risk factor data and breast cancer rates in large databases of women. The Gail model used detailed data collected on 284,780 women who participated in the Breast Cancer Detection Demonstration Project. This model incorporates family history of breast cancer in first-degree relatives, menstrual history, reproductive history, and history of benign breast disease.<sup>8</sup> The Claus model was developed from data from the Cancer and Steroid Hormone study conducted by the Center for Disease Control in 4730 patients and 4688 control subjects.<sup>9</sup> The Claus model provides age-specific lifetime estimates of breast cancer risk based on a family history of breast cancer and age at diagnosis in as many as 2 relatives.

After identification of the *BRCA1* and *BRCA2* genes, additional models were developed based on correlations between the results of genetic testing and the family histories of the women tested. These include the Couch,<sup>10</sup> Shattuck-Eidens (Myriad I),<sup>11</sup> and Frank (Myriad II)<sup>12</sup> models. BRCAPRO is a computer-based model that uses Bayesian analysis based on published breast and ovarian

**Table 2** Overlap Among Patients Meeting Criteria for Each Model

Model	Patients Meeting Criteria	Patients Studied
Myriad II	112	2.2
Hartmann	114	2.3
Claus	50	1.0
Myriad II and Hartmann	72	1.4
Myriad II and Claus	9	0.2
Hartmann and Claus	39	0.8
Myriad II, Hartmann, and Claus	70	1.4
Total	466	9.2

cancer incidence and penetrance rates to estimate hereditary risk.<sup>13</sup> The Hartmann model was based on known risk factors for *BRCA* mutations to enable a retrospective analysis of women who underwent bilateral prophylactic mastectomy at the Mayo Clinic.<sup>14</sup> Finally, Myriad Genetics Laboratories, Inc., posts recommendations when to perform genetic testing on its Web site.<sup>15</sup>

Currently, only patients with compelling risk factors are referred for genetic risk assessment and only if they or their providers recognize that risk. Various models are then applied to quantify the patient's risk and to assist in the decision of whether to recommend testing. The models listed herein are useful in the setting of a risk-assessment clinic but have not yet been applied to a screening population for breast or ovarian cancer. We applied 3 of these models (Myriad II, Hartmann, and Claus) to a population of women without cancer to determine their utility as screening tools for women at risk of hereditary breast and ovarian cancer and to determine the prevalence of high risk in that population.

## Materials and Methods

With institutional review board approval, we performed a retrospective review of data collected on all unaffected women presenting for mammography at the Massachusetts General Hospital Avon Comprehensive Breast Center over a 14-week period from May 12 to August 18, 2003. Patients with a personal history of breast or ovarian cancer were excluded. Patients routinely completed a 35-item self-administered scan-compatible questionnaire that included information on personal cancer history, family history of breast or ovarian cancer, and Ashkenazi Jewish ancestry (Appendix 1). The age range (< 35, 36-39, 40-50, and > 50 years) at diagnosis for every family member with breast or ovarian cancer was solicited. Bilateral breast cancer was not captured by this form. All forms were immediately scanned into a Microsoft Access database and the information was available to clinicians the same day for patient care. We analyzed the data collected over the 14-week period using de-identified information.

We identified 3 models to evaluate hereditary risk of



**Table 3** Myriad II Criteria Associated with > 10% Risk of Mutation in Patients Without Cancer<sup>12</sup>

Original Criteria
Non-Ashkenazi: breast cancer at age < 50 in ≥ 2 relatives, no ovarian cancer
Non-Ashkenazi: breast cancer at age < 50 and ovarian cancer at any age
Ashkenazi: breast cancer at age < 50 years in 1 relative, no ovarian cancer
Ashkenazi: breast cancer at age < 50 years in ≥ 2 relatives, no ovarian cancer
Ashkenazi: ovarian cancer any age in 1 relative, no breast cancer at age < 50 years
Ashkenazi: ovarian cancer any age in ≥ 2 relatives, no breast cancer at age < 50 years
Ashkenazi: breast cancer at age < 50 years and ovarian cancer at any age
Modified Criteria
Non-Ashkenazi plus breast cancer at age ≤ 50 years in ≥ 2 relatives*
Non-Ashkenazi plus breast cancer at age ≤ 50 in 1 relative plus ovarian cancer at any age*
Ashkenazi plus breast cancer at age ≤ 50 years in 1 relative
Ashkenazi plus ovarian cancer at any age in 1 relative

\*Same bloodline.

breast and ovarian cancer that were appropriate for use as screening tools in women without cancer (Tables 1-4)<sup>9,12</sup>: the Claus model, the Frank (Myriad II) model, and the Hartmann model. Criteria from each model associated with a 10% risk of mutation or a 21% lifetime risk of breast cancer were used. A 10% risk of mutation was chosen according to the 1996 American Society of Clinical Oncology guidelines for genetic testing referral<sup>16</sup> and used for the Frank model, in which risk factors are associated with a prevalence or risk of a *BRCA* mutation. The Claus criteria provide a lifetime risk of breast cancer development rather than risk of mutation carrier status, and a 21% lifetime risk threshold (an approximate doubling of the lifetime risk) was used.<sup>17,18</sup> The Hartmann model is divided into high-risk and moderate-risk groups; we used the high-risk criteria.

Given variation in data elements in various models, including age ranges, the selected criteria were then modified to conform to our available data. Specifically, the age ranges were changed from < 50 years to ≤ 50 years in the Myriad and Claus models, with additional age adjustments for the Claus model, as we did not have an age breakdown for women > 50 or < 36 years of age. We eliminated the criterion for bilateral breast cancer from the Hartmann model, potentially missing a small number of women, and changed the age in one of the Hartmann criteria from < 45 years to ≤ 50 years. Overall, these changes may be expected to slightly increase the number of women

**Figure 1** Patients Meeting Criteria of Each Model**Figure 2** Risk Assessment Referrals per Day

considered to be at high risk. Initial and modified model criteria are listed in Tables 3, 4, and 5.<sup>9,12,14</sup> The database was queried to determine the number of women who met these modified criteria for each model and combination of models. The average number of patients meeting criteria per day was calculated using the average number of women without cancer undergoing mammography per day at the Avon Comprehensive Breast Center.

## Results

From May 12 to August 18, 2003, 5,736 women completed the questionnaire, of whom 695 with a personal history of breast or ovarian cancer were excluded. Family histories of the remaining 5,041 women (an average of 60 per day) were evaluated according to the modified criteria for each model. Totals of 5.9% and 5.2% of patients met the Hartmann and Myriad II criteria, respectively, and 3.3% of patients met the Claus criteria (Figure 1). This corresponds to an average of 3.5, 3.1, and 1.9 patients per day for the Hartmann, Myriad II, and Claus models, respectively (Figure 2). Four hundred sixty-six patients, or 9.2% of patients studied, met the

**Table 4** Claus Criteria Associated with > 21% Lifetime Risk of Breast Cancer<sup>9</sup>

Original Criteria
1 first-degree relative with breast cancer at age < 30 years
1 first-degree relative with breast cancer at age < 40 years, 1 first-degree relative with breast cancer at age < 80 years
1 first-degree relative with breast cancer at age < 50 years, 1 first-degree relative with breast cancer at age < 70 years
2 first-degree relatives with breast cancer at age < 60 years
Mother with breast cancer at age < 40 years, maternal aunt with breast cancer at age < 80 years
Mother with breast cancer at age < 50 years, maternal aunt with breast cancer at age < 70 years
Mother with breast cancer at age < 60 years, maternal aunt with breast cancer at age < 60 years
Mother with breast cancer at age < 70 years, maternal aunt with breast cancer at age < 50 years
Mother with breast cancer at age < 80 years, maternal aunt with breast cancer at age < 40 years
Mother with breast cancer at age < 30 years, paternal aunt with breast cancer at age < 70 years (< 80 years = 21.0%)
Mother with breast cancer at age < 50 years, paternal aunt with breast cancer at age < 30 years
1 second-degree relative with breast cancer at age < 30 years, 1 second-degree relative with breast cancer at age < 70 years*
1 second-degree relative with breast cancer at age < 40 years, 1 second-degree relative with cancer at age < 50 years*
Modified Criteria
1 first-degree relative with breast cancer at age < 36 years
1 first-degree relative with breast cancer at age < 50 years plus 1 first-degree relative with breast cancer any age
2 first-degree relatives with breast cancer at age < 50 years
Mother with breast cancer at age < 50 years plus maternal aunt with breast cancer at any age
Mother with breast cancer any age plus maternal aunt with breast cancer at age < 50 years
Mother with breast cancer at age < 36 years plus paternal aunt with breast cancer at any age
Mother with breast cancer at age < 50 years plus paternal aunt with breast cancer at age < 36 years
1 second-degree relative with breast cancer at age < 36 years plus 1 second-degree relative with breast cancer at any age*
1 second-degree relative with breast cancer at age < 40 years plus 1 second-degree relative with breast cancer at age < 50 years*

\*Same bloodline.

criteria for ≥ 1 model (Table 2). Seventy patients (1.4%) met the criteria for all 3. Only 15% of patients who met criteria for ≥ 1 model met the criteria for all 3. Although the numbers of women identified may be slightly higher than if we had not modified the criteria, our changes would not be expected to affect the overlap among models.

**Table 5** Hartmann High-Risk Criteria<sup>14</sup>

Original Criteria
≥ 2 first-degree relatives with breast cancer
1 first-degree relative plus ≥ 2 second- or third-degree relatives with breast cancer
1 first-degree relative with breast cancer at age < 45 years plus 1 other relative with breast cancer
1 first-degree relative with breast cancer plus ≥ 1 relatives with ovarian cancer
2 second- or third-degree relatives with breast cancer plus ≥ 1 relative with ovarian cancer
1 second or third-degree relative with breast cancer plus ≥ 2 relatives with ovarian cancer
≥ 3 second- or third-degree relatives with breast cancer
1 first-degree relative with bilateral breast cancer
Modified Criteria
≥ 2 first-degree relatives with breast cancer
1 first-degree relative plus ≥ 2 second- or third-degree relatives with breast cancer*
1 first-degree relative with breast cancer at age < 50 years plus 1 other relative with breast cancer*
1 first-degree relative with breast cancer plus ≥ 1 relative with ovarian cancer*
2 second or third-degree relatives with breast cancer plus ≥ 1 relatives with ovarian cancer*
1 second or third-degree relative with cancer plus ≥ 2 relatives with ovarian cancer*
≥ 3 second- or third-degree relatives with breast cancer*

\*Same bloodline.

### Discussion

In this retrospective data analysis, 3.3%-5.9% of women without breast or ovarian cancer undergoing mammography were found to be at risk for hereditary *BRCA1* or *BRCA2* mutations by ≥ 1 of 3 accepted models, and 9.2% were found to be at risk when all 3 models were used. These results are similar to the findings of Hughes et al, who found a 6% prevalence of family histories suspicious for hereditary breast and ovarian cancer in a primary care practice with use of broad criteria followed by pedigree review by a surgical oncologist experienced in risk assessment.<sup>19</sup>

Further evaluation reveals surprisingly little overlap among patients meeting the criteria for each model (Table 2). Although 9.2% of patients met criteria for ≥ 1 model, only 1.4% met criteria for all 3. For patients who met the Myriad II or Hartmann criteria, 27% and 24%, respectively, met the criteria for the other. Among patients who met the Claus criteria, 5% and 23% met criteria for the Myriad II and Hartmann models, respectively. Therefore, choosing the appropriate model for screening for hereditary risk is more complicated than determining the desired sensitivity; use of any one of these models alone may miss large numbers of women at risk.

Several models were not used for various reasons. The Gail model underestimates the risk of breast cancer in women with hereditary mutations and is not appropriate for evaluation of hereditary risk.<sup>20</sup> The Couch model describes the risk of a *BRCA1* mutation among women with breast cancer and is therefore not applicable to a screening population, nor does it address *BRCA2*. The Myriad I model was designed in a similar fashion. BRCAPRO, although considered a highly accurate tool for risk assessment, requires a significant amount of time for data entry and was believed to be impractical for large-scale screening. It is best applied to selected patients at very high risk, perhaps as a second-stage screen for women identified by the aforementioned criteria. The online Myriad recommendations for risk assessment include screening of anyone with a relative who has had breast cancer before the age of 50 and were believed to be too broad for useful screening.

Generally, risk assessment and counseling requires 1-2 hours for the initial visit plus additional visits if genetic testing is elected. Using our current approach to counseling, it would take tremendous resources to manage the number of women identified in our mammography program who should be referred for risk assessment. Based on the data presented, there is not a single model on which we can base calculations of the resources necessary to meet the needs of these women. A single reliable model would allow more definitive calculation of number of women at high risk and would facilitate calculation of the required resources. Considering that women < 40 years of age generally do not undergo mammography, the number of women at risk would be expected to increase if screening for a *BRCA1* or *BRCA2* mutation were applied to a broader population than we have reported.

## Conclusion

Breast cancer risk assessment is becoming increasingly important, as we are better able to provide risk-reduction therapies. We developed a system to collect family histories in the course of screening mammography, and, with modifications of currently available models, were able to identify a large number of women who need risk assessment. The problem the medical community must now address is how to manage this immense population and/or find ways to decrease the number of women considered to be at high risk. We need to develop an accurate and focused model that would allow more precise identification of those at risk. Risk assessment resources could then be directed to a smaller number of women. However, this is not an easy task. BRCAPRO, the computerized model currently used in many high-risk clinics, comes closest in terms of accuracy, but, as currently used, is inappropriate for screening. In addition, we need to develop new approaches to risk assessment and counseling that are simpler and more efficient. More women could then undergo risk assessment, with remaining resources targeted to the identified mutation carriers. This

dual approach may allow us to manage the large number of women at risk. We continue to work on practical ways to identify the large numbers of women potentially at risk for hereditary breast and ovarian cancer and to make risk assessment available to these women.


## Acknowledgements

This research was supported in part by the Boston Race for the Cure, an affiliate of the Susan G. Komen Breast Cancer Foundation; the Charles E. Dana Foundation; and the Robert E. Wise Foundation.

## References

1. Domchek SM, Eisen A, Calzone K, et al. Application of breast cancer risk prediction models in clinical practice. *J Clin Oncol* 2003; 21:593-601.
2. Meijers-Heijboer H, Van Geel B, Van Putten WLJ, et al. Breast cancer after prophylactic bilateral mastectomy in women with a *BRCA1* or *BRCA2* mutation. *N Engl J Med* 2001; 345:159-164.
3. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a *BRCA1* or *BRCA2* mutation. *N Engl J Med* 2002; 346:1609-1615.
4. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of *BRCA1* or *BRCA2* mutations. *N Engl J Med* 2002; 346:1616-1622.
5. Rebbeck TR, Weber BL. Letter to the editor. *N Engl J Med* 2002; 347:1039-1040.
6. Narod SA, Brunet JS, Ghadirian P, et al, for the Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in *BRCA1* and *BRCA2* mutation carriers: a case-control study. *Lancet* 2000; 356:1876-1881.
7. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in *BRCA1* and *BRCA2*. *JAMA* 2001; 286:2251-2256.
8. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989; 81:1879-1886.
9. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. *Cancer* 1994; 73:643-651.
10. Couch FJ, DeShano ML, Blackwood MA, et al. *BRCA1* mutations in women attending clinics that evaluate the risk of breast cancer. *N Engl J Med* 1997; 336:1409-1415.
11. Shattuck-Eidens D, Oliphant A, McClure M, et al. *BRCA1* sequence analysis in women at high risk for susceptibility mutations: risk factor analysis and implications for genetic testing. *JAMA* 1997; 278:1242-1250.
12. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in *BRCA1* and *BRCA2*: analysis of 10,000 individuals. *J Clin Oncol* 2002; 20:1480-1490.
13. Berry DA, Iversen ES, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of *BRCA1/BRCA2*, and prevalence of other breast cancer susceptibility genes. *J Clin Oncol* 2002; 20:2701-2712.
14. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med* 1999; 340:77-84.
15. Identifying patients at risk for HBOC; December 15, 2003. Available at: [http://www.myriadtests.com/provider/id\\_hboc.htm](http://www.myriadtests.com/provider/id_hboc.htm). Accessed: .
16. ASCO. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. *J Clin Oncol* 1996; 14:1730-1736.
17. Gilpin CA, Carson N, Hunter AGW. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. *Clin Genet* 2000; 58:299-308.
18. Hampel H, Sweet K, Westman JA, et al. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. *J Med Genet* 2004; 41:81-91.
19. Hughes KS, Roche C, Campbell C, et al. Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire. *Breast J* 2003; 9:19-25.
20. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. *J Clin Oncol* 1996; 14:103-110.

Appendix 1 Need a title for this



**Avon Foundation  
Comprehensive  
Breast Evaluation Center  
AT MASSACHUSETTS  
GENERAL HOSPITAL**

## BREAST HEALTH PROFILE

**IDENT INFORMATION**

English Name: \_\_\_\_\_  
 Spanish Name: \_\_\_\_\_  
 Race: \_\_\_\_\_  
 Sex: \_\_\_\_\_

1. Please enter your usual height and weight.  
 An doctor's response is important!

HEIGHT		WEIGHT (in pounds)	
Feet	Inches	Pounds	Kilograms
5	0	100	45.4
5	1	105	47.6
5	2	110	49.9
5	3	115	52.1
5	4	120	54.4
5	5	125	56.7
5	6	130	59.0
5	7	135	61.3
5	8	140	63.5
5	9	145	65.8
5	10	150	68.1
5	11	155	70.4
5	12	160	72.7
6	0	165	75.0
6	1	170	77.3
6	2	175	79.6
6	3	180	81.9
6	4	185	84.2
6	5	190	86.5
6	6	195	88.8
6	7	200	91.1
6	8	205	93.4
6	9	210	95.7
6	10	215	98.0
6	11	220	100.3
6	12	225	102.6
7	0	230	104.9
7	1	235	107.2
7	2	240	109.5
7	3	245	111.8
7	4	250	114.1
7	5	255	116.4
7	6	260	118.7
7	7	265	121.0
7	8	270	123.3
7	9	275	125.6
7	10	280	127.9
7	11	285	130.2
7	12	290	132.5
8	0	295	134.8
8	1	300	137.1
8	2	305	139.4
8	3	310	141.7
8	4	315	144.0
8	5	320	146.3
8	6	325	148.6
8	7	330	150.9
8	8	335	153.2
8	9	340	155.5
8	10	345	157.8
8	11	350	160.1
8	12	355	162.4
9	0	360	164.7
9	1	365	167.0
9	2	370	169.3
9	3	375	171.6
9	4	380	173.9
9	5	385	176.2
9	6	390	178.5
9	7	395	180.8
9	8	400	183.1
9	9	405	185.4
9	10	410	187.7
9	11	415	190.0
9	12	420	192.3
10	0	425	194.6
10	1	430	196.9
10	2	435	199.2
10	3	440	201.5
10	4	445	203.8
10	5	450	206.1
10	6	455	208.4
10	7	460	210.7
10	8	465	213.0
10	9	470	215.3
10	10	475	217.6
10	11	480	219.9
10	12	485	222.2
11	0	490	224.5
11	1	495	226.8
11	2	500	229.1
11	3	505	231.4
11	4	510	233.7
11	5	515	236.0
11	6	520	238.3
11	7	525	240.6
11	8	530	242.9
11	9	535	245.2
11	10	540	247.5
11	11	545	249.8
11	12	550	252.1
12	0	555	254.4
12	1	560	256.7
12	2	565	259.0
12	3	570	261.3
12	4	575	263.6
12	5	580	265.9
12	6	585	268.2
12	7	590	270.5
12	8	595	272.8
12	9	600	275.1
12	10	605	277.4
12	11	610	279.7
12	12	615	282.0

2. What is your current life style?

Smoking:  Never  Occ  Reg  Quit  Occ  Reg  Quit  Occ  Reg  Quit  Occ  Reg  Quit

Alcohol:  Never  Occ  Reg  Quit  Occ  Reg  Quit  Occ  Reg  Quit

**REFERRAL HISTORY**

1. Please enter the doctor who referred you.

Doctor Name: \_\_\_\_\_  
 Clinic Name: \_\_\_\_\_

2. Have you had a previous mammogram?  
 Yes  No

3. Have any other doctors referred you?  
 Yes  No

If not at MGH, where was the most recent done?

Hospital: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_\_

4. What ages did you have a mammogram? (Start at least age 40)

<input type="checkbox"/> 40-44	<input type="checkbox"/> 45-49	<input type="checkbox"/> 50-54
<input type="checkbox"/> 45-49	<input type="checkbox"/> 50-54	<input type="checkbox"/> 55-59
<input type="checkbox"/> 50-54	<input type="checkbox"/> 55-59	<input type="checkbox"/> 60-64
<input type="checkbox"/> 55-59	<input type="checkbox"/> 60-64	<input type="checkbox"/> 65-69
<input type="checkbox"/> 60-64	<input type="checkbox"/> 65-69	<input type="checkbox"/> 70-74
<input type="checkbox"/> 65-69	<input type="checkbox"/> 70-74	<input type="checkbox"/> 75-79
<input type="checkbox"/> 70-74	<input type="checkbox"/> 75-79	<input type="checkbox"/> 80-84
<input type="checkbox"/> 75-79	<input type="checkbox"/> 80-84	<input type="checkbox"/> 85-89
<input type="checkbox"/> 80-84	<input type="checkbox"/> 85-89	<input type="checkbox"/> 90-94
<input type="checkbox"/> 85-89	<input type="checkbox"/> 90-94	<input type="checkbox"/> 95-99
<input type="checkbox"/> 90-94	<input type="checkbox"/> 95-99	<input type="checkbox"/> 1000

**REPRODUCTIVE HISTORY**

1. Have you ever had breast cancer? (if yes when?)

<input type="radio"/> Yes	<input type="radio"/> No	
<input type="checkbox"/> 1950-1959	<input type="checkbox"/> 1960-1969	<input type="checkbox"/> 1970-1979
<input type="checkbox"/> 1980-1989	<input type="checkbox"/> 1990-1999	<input type="checkbox"/> 2000-2009
<input type="checkbox"/> 2010-2019	<input type="checkbox"/> 2020-2029	<input type="checkbox"/> 2030-2039

**BREAST HISTORY (Cont.)**

**INDICATIONAL** - Please fill in the 2 white (left breast) and/or 2 white (right breast) for every time period that the procedure occurred.

**BY COMPLET** - A procedure from the left breast. Complete by checking the box.

<input type="checkbox"/> Yes	<input type="checkbox"/> No	
<input type="checkbox"/> 1950-1959	<input type="checkbox"/> 1960-1969	<input type="checkbox"/> 1970-1979
<input type="checkbox"/> 1980-1989	<input type="checkbox"/> 1990-1999	<input type="checkbox"/> 2000-2009
<input type="checkbox"/> 2010-2019	<input type="checkbox"/> 2020-2029	<input type="checkbox"/> 2030-2039

2. Have you ever had fluid drained from a breast cyst?  
 (if yes when?)

<input type="checkbox"/> Yes	<input type="checkbox"/> No	
<input type="checkbox"/> 1950-1959	<input type="checkbox"/> 1960-1969	<input type="checkbox"/> 1970-1979
<input type="checkbox"/> 1980-1989	<input type="checkbox"/> 1990-1999	<input type="checkbox"/> 2000-2009
<input type="checkbox"/> 2010-2019	<input type="checkbox"/> 2020-2029	<input type="checkbox"/> 2030-2039

3. Have you ever had a breast infection or abscess treated?  
 (if yes when?)

<input type="checkbox"/> Yes	<input type="checkbox"/> No	
<input type="checkbox"/> 1950-1959	<input type="checkbox"/> 1960-1969	<input type="checkbox"/> 1970-1979
<input type="checkbox"/> 1980-1989	<input type="checkbox"/> 1990-1999	<input type="checkbox"/> 2000-2009
<input type="checkbox"/> 2010-2019	<input type="checkbox"/> 2020-2029	<input type="checkbox"/> 2030-2039

4. Have you ever had a breast implant? (if yes when?)

<input type="checkbox"/> Yes	<input type="checkbox"/> No	
<input type="checkbox"/> 1950-1959	<input type="checkbox"/> 1960-1969	<input type="checkbox"/> 1970-1979
<input type="checkbox"/> 1980-1989	<input type="checkbox"/> 1990-1999	<input type="checkbox"/> 2000-2009
<input type="checkbox"/> 2010-2019	<input type="checkbox"/> 2020-2029	<input type="checkbox"/> 2030-2039

5. Have you ever had breast reduction surgery? (if yes when?)

<input type="checkbox"/> Yes	<input type="checkbox"/> No	
<input type="checkbox"/> 1950-1959	<input type="checkbox"/> 1960-1969	<input type="checkbox"/> 1970-1979
<input type="checkbox"/> 1980-1989	<input type="checkbox"/> 1990-1999	<input type="checkbox"/> 2000-2009
<input type="checkbox"/> 2010-2019	<input type="checkbox"/> 2020-2029	<input type="checkbox"/> 2030-2039

**MENSTRUAL HISTORY**

1. At what age did you begin having your period?  
 9-10  11  12  13  14  15  16  17

2. How long periods stopped?  
 Yes  No

If not, when you enter they stopped?

<input type="checkbox"/> 1950-1959	<input type="checkbox"/> 1960-1969	<input type="checkbox"/> 1970-1979	<input type="checkbox"/> 1980-1989	<input type="checkbox"/> 1990-1999
<input type="checkbox"/> 2000-2009	<input type="checkbox"/> 2010-2019	<input type="checkbox"/> 2020-2029	<input type="checkbox"/> 2030-2039	<input type="checkbox"/> 2040-2049
<input type="checkbox"/> 2050-2059	<input type="checkbox"/> 2060-2069	<input type="checkbox"/> 2070-2079	<input type="checkbox"/> 2080-2089	<input type="checkbox"/> 2090-2099

3. Have you had a hysterectomy?  
 Yes  No

If yes, how old were you when you had the hysterectomy?  
 1950-1959  1960-1969  1970-1979  1980-1989  1990-1999  2000-2009  2010-2019  2020-2029  2030-2039  2040-2049  2050-2059

How 50% of your uterus removed?  
 Yes  No

**PERINATAL HISTORY**

1. How many times have you been pregnant?  
 0  1  2  3  4  5  6  7  8  9  10  11  12

How many children have you had?  
 None  1  2  3  4  5  6  7  8  9  10  11  12

Appendix 2 Need a title for this

**HORMONES**

1. Do you ever or have you ever used, birth control pills?

No ever  Occasionally  Yes, in the past  Yes ever

If Yes, what age did you start taking them?

Under 18  18-20  21-30  
 31-40  41-50  51-60

Overall, how many years did you take them?

Less than 1 year  1-4 years  More than 5 years

1 year  5 years  10 years  
 15 years  20-30 years  30+ years

Did you use the pill continuously during this time?

Yes  No

2. Have you ever used, or do you use, estrogen or estrogen replacement therapy (includes OTC and includes birth control pills)?

Yes  No

If Yes, what age did you start taking them?

Under 18  18-20  21-30  
 31-40  41-50  51-60

Overall, how many years did you take them?

Less than 1 year  1-4 years  More than 5 years

1 year  5 years  10 years  
 15 years  20-30 years  30+ years

Did you use the hormone continuously during this time?

Yes  No

Are you using them now?

Yes  No

3. How often have you taken drugs to increase fertility?

4. How often have you taken \_\_\_\_\_ Fertility?

5. How often have you taken \_\_\_\_\_ Fertility (Inject)?

6. How often have you taken \_\_\_\_\_ Fertility?

**FAMILY HISTORY OF CANCER**

1. Mark the chart below for blood relatives.

Relationship	MOTHER		FATHER		SIBLING	
	First	Second	First	Second	First	Second
Brother	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Sister	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Daughter	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Brother-in-law	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Sister-in-law	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Grandmother	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Grandfather	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Uncle	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Aunt	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Nephew	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Niece	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Did anyone in your family have breast cancer?  Yes  No

**PREVIOUS**

**SEX**

**AGE**

**BREAST SELF-EXAMINATION**

1. Do you practice breast self-examination?

Never  Occasionally  Always

**BREAST CANCER TREATMENT**

1. Have you had a mastectomy?

Yes  No

If Yes, what type?

Total mastectomy  Partial mastectomy

2. Have you ever had any radiation therapy to your breast?

Yes  No

3. Have you ever had chemotherapy?

Yes  No

**OTHER MEDICAL HISTORY**

1. In the past 5 years, have you ever had any of the following types of cancer (includes breast cancer)? Please mark all that apply (do not include breast or basal cell cancer).

Prostate cancer  Ovarian cancer  
 Stomach cancer  Colon/rectum cancer  
 Esophagus cancer  Lung cancer  
 Kidney cancer  Bladder cancer  
 Pancreatic cancer  Thyroid cancer

**PATIENT BACKGROUND INFORMATION**

1. Are you of Spanish/Hispanic origin?

Yes  No  Other

2. Select what best describes your racial background (Choose one).

Caucasian or White  
 African American or Black  
 Asian or Pacific Islander  
 Hispanic/Latino, Mexican or Latin  
 American Indian/Alaska Native  
 Other (Please specify) \_\_\_\_\_  
 Other

3. Were any of your grandparents of African/Caribbean descent?

Yes  No  Unsure

I hereby authorize Massachusetts General Hospital to obtain any of my previous X-rays.

\_\_\_\_\_  
 (Print name)

\_\_\_\_\_  
 (Print address)

\_\_\_\_\_  
 (Print city and state)